Awards Nomination 20+ Million Readerbase
Indexed In
  • Academic Journals Database
  • Open J Gate
  • Genamics JournalSeek
  • Academic Keys
  • JournalTOCs
  • China National Knowledge Infrastructure (CNKI)
  • CiteFactor
  • Scimago
  • Ulrich's Periodicals Directory
  • Electronic Journals Library
  • RefSeek
  • Hamdard University
  • EBSCO A-Z
  • OCLC- WorldCat
  • SWB online catalog
  • Virtual Library of Biology (vifabio)
  • Publons
  • MIAR
  • University Grants Commission
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • Google Scholar
Share This Page
Journal Flyer
Flyer image
The what million dollar question: Patent litigation and strategy under the Biologics Price Competition and Innovation Act
International Conference and Exhibition on Biowaivers & Biosimilars
September 10-12, 2012 Hilton San Antonio Airport, USA

Bryan J. Vogel

Scientific Tracks Abstracts: J Bioequiv Availab

Abstract:

Umbilical cord and placenta, once considered medical waste are emerged to be a valuable source of stem cells. The cord blood stem cells show the potential to treat the fatal disease such as leukemia, cardiac attacks and debilitating disease including Alzeimer?s and Parkinson?s. Cord blood stem cells are also widely used in therapies such as blood disorders, bone and tissue engineering, dermatology etc. Isolated NPCs are able to proliferate in response to basic fibroblast growth factor and when the culture conditions are altered means addition of BDNF and NT-3, they differentiate into several phenotypes of neurons. Fabricated PCL with 10% sucrose and 10% PEG 4000 scaffold shown good proliferation rate upto 14 days while PCL with 5% sucrose shown to promote good cells attachement and survival rate more than 21 days this may be due to pore size & pore number. Intravenously transplanted NPCs can enter the mice brain with Parkinson disease, survive, migrate and improve functional recovery. Transplantation of human NPCs can be used to restore neurological deficits in experimental Parkinson disease

Biography :

Bryan J. Vogel is a partner in the New York office of the law firm of Robins, Kaplan, Miller, & Ciresi L.L.P. He is an Intellectual Property litigator with a practice emphasis in Life Sciences and Hatch-Waxman and biosimilars ligation and strategic counseling. He publishes frequently on general Intellectual Property topics, as well as matters specific to the Life Sciences community. He received his J.D. from George Washington University. In addition, he earned a B.S. in Chemical Engineering, with honors from Michigan State University, where he was also a member of Phi Beta Kappa and Tau Beta Pi (invited)